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Introduction
There has been a significant increase in the pre-
scription of antipsychotic medication in the com-
munity. While this increase is not specific to 
pregnancy it includes prescription to women 
across the fertile years. A study of Australian pre-
scribing between 2000 and 2011 found a 217.7% 
increase in the prescription of atypical antipsy-
chotics, which makes it now the third most com-
monly prescribed psychotropic [Stephenson et al. 
2013]. Alexander and colleagues, in a study of the 
use of antipsychotics in the US, also found an 
increase that was not accounted for by use in psy-
chotic illnesses [Alexander et al. 2011]. Both sets 
of authors postulated that much of the increase 
seen is for off-label use and for wider indications 
than psychosis alone. The lifetime prevalence for 
schizophrenia is approximately 1% and bipolar 
disorder is approximately 2%, making these con-
ditions in pregnancy relatively low prevalence. 
The trend in wider utilization of antipsychotics in 
the community makes understanding the risk 
profile in pregnancy essential for clinicians man-
aging women in their fertile years. This is particu-
larly relevant when consideration is given to the 
nearly 49% rate of unplanned pregnancies in the 
community [Finer and Henshaw, 2006].
At present, any comfort we may have in prescrib-
ing antipsychotics during pregnancy comes 
mainly from the absence of negative data rather 
than the presence of positive data. It has been 
estimated that at least 500 cases are needed for 
each individual medication to determine differ-
ences in occurrence of major malformation and 
larger numbers are required to adequately control 
for other variables [Meador et al. 2008]. To date, 
none of the first generation antipsychotics (FGAs) 
or second generation antipsychotics (SGAs) has 
been adequately investigated in this regard. The 
issue is further complicated by the fact that the 
majority of studies that aim to evaluate and clarify 
teratogenic risk associated with antenatal expo-
sure to psychotropic medications were not 
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designed to control for possible teratogenic effects 
of the underlying psychiatric disorder. We await 
further clarity from prospective registry studies 
that include a nontreatment control group.
When consideration is given to the risk benefit 
profile of pharmacological treatment in preg-
nancy, the consideration of risks of not treating is 
usually factored into the equation. With off-label 
use and indications where the evidence for effi-
cacy is limited this is challenging. However, when 
focusing on the two mental disorders with clear 
indications for these medications, i.e. schizophre-
nia and bipolar disorder, the risks of untreated ill-
ness are significant. Both schizophrenia and 
bipolar disorder have been associated with an 
increased risk of pregnancy complications such as 
placental abnormalities, antepartum hemorrhage, 
prematurity, pre-eclampsia, low birth-weight, 
intrauterine growth retardation, fetal distress, 
neonatal hypoglycemia, low Apgar score, stillbirth 
and congenital defects, as well as the potential for 
adverse neurodevelopmental outcomes independ-
ent of any risk associated with exposure to antip-
sychotic medication [Jablensky et al. 2005; Boden 
et al. 2012; Abel and Howard, 2014]. A study of 
Western Australian women with schizophrenia 
showed an increased risk of placental abruption; 
this study also showed women with either schizo-
phrenia and bipolar had an increased risk of 
antepartum hemorrhage compared with controls 
even after controlling for a range of confounding 
variables [respectively: odds ratio (OR) 2.75, 95% 
confidence interval (CI) 1.32–5.74; OR 1.65, 
95% CI 1.02–2.69; OR 1.66, 95% CI 1.15–2.39) 
[Jablensky et al. 2005]. In addition to pregnancy 
complications associated with serious mental ill-
ness, there are also longer term concerns about 
parenting and child development if a women 
becomes or remains unwell due to the cessation 
or undertreatment of her illness.
As there is an increasing fertility rate within this 
population of women with psychotic illnesses – 
due in part to both the success of modern treat-
ments which includes the availability of prolactin 
sparing options and the tendency to manifest dur-
ing the reproductive years – all clinicians will at 
some time need to consider the inherent risks of 
treatment and nontreatment in the perinatal set-
ting [Galbally et al. 2010; Gentile, 2010]. Ideally, 
this is discussed with a woman prior to pregnancy. 
When consideration is made to continue treat-
ment in pregnancy, often a history of response to 
a particular medication is relevant to this decision 
given the risks to maternal mental health of 
changing to a medication which is then found not 
to be effective for an individual.
There remains a lack of clarity regarding the nat-
ural course of psychotic illnesses during preg-
nancy. It has been proposed that this altered 
physiological and psychological state may exert a 
favorable effect on the course of illness [Grof et al. 
2000]; however, more recent studies suggest an 
elevated recurrence rate [Viguera et al. 2011]. A 
1995 literature review reported that patients with 
schizophrenia who stop taking antipsychotic 
medication have a cumulative relapse rate of 53% 
over a 10-month period compared with 16% 
among patients who continue treatment [Gilbert 
et  al. 1995]. Rapid withdrawal that frequently 
accompanies the diagnosis of pregnancy, early 
onset of illness, younger age, high antipsychotic 
dose requirement and recent psychiatric hospi-
talization have all been found to be predictors of 
relapse [Baldessarini and Viguera, 1995]. 
Similarly, in a prospective study that examined 
the effects of mood stabilizer cessation during 
pregnancy, those women with bipolar disorder 
were more than twice as likely to relapse in preg-
nancy (85.5% versus 37%) compared with women 
who continued treatment [Viguera et  al. 2007]. 
Thus, pregnancy needs to be considered to be a 
high-risk period for relapse, particularly in the 
setting of discontinuation of maintenance 
treatment.
The uses of antipsychotic medications have 
increasingly extended beyond their use in schizo-
phrenia and bipolar disorder, and are frequently 
being prescribed for mood and anxiety disorders, 
self-harming behaviors, trauma-related conditions 
and even insomnia. Thus, it is essential that an 
adequate risk benefit analysis be performed when-
ever any medication is being prescribed in the 
perinatal setting, or if there is a potential for preg-
nancy, and a process of obtaining informed con-
sent adhered to. Consideration needs to be given 
to the risks of teratogenesis, obstetric complica-
tions, impairment of neonatal adaption and nega-
tive neurodevelopmental outcome. Once decisions 
are made and enacted a comprehensive plan for 
obstetric, pediatric and psychiatric monitoring 
needs to be put in place [Galbally et al. 2010].
Risk of structural teratogenicity
All antipsychotics cross the placenta [Newport 
et al. 2007] and, as such, consideration needs to 
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be given to their potential to cause structural or 
functional dysgenesis of fetal organs and/or skel-
etal structures when exposure occurs in first tri-
mester. It is generally considered that the baseline 
population rate for malformation in the general 
population is 1–3%.
Most of the FGAs have been available for around 
four decades and share the action of D2 receptor 
blockade throughout the brain, in particular the 
mesolimbic system. A comprehensive literature 
review was unable to identify any teratogenic risk 
associated with the use of promethazine, chlor-
promazine, prochlorperazine, haloperidol, per-
phenazine, trifluoperazine, loxapine, thioridazine, 
flupenthixol or fluphenazine [Einarson and 
Boskovic, 2009]. However, the authors warned 
that less rigorous research standards and flawed 
methodologies limit our ability to accept these 
findings without question. The SGAs are newer 
agents that share a mechanism of action that 
involves a relatively potent blockade of 5-HT(2A) 
receptors coupled with transient occupation of 
the D2 receptor. The same review examined all 
available data regarding fetal exposure to clozap-
ine, risperidone, olanzapine, quetiapine, ziprasi-
done and aripiprazole [Einarson and Boskovic, 
2009], and no clear association with any specific 
malformation has emerged. However, no single 
agent has begun to approximate the 500 recorded 
and examined exposures required to determine 
differences in the occurrence of malformation.
A Swedish Medical Birth Register study found 
that maternal use of antipsychotic medication 
(grouping both FGAs and SGAs) was associated 
with a small, but statistically significant increased 
risk of major malformation (mainly atrium or 
ventricular septum defects) [OR 1.52 (1.05–2.19) 
with 95% CI adjusted for year of birth, maternal 
age, parity, smoking and previous miscarriages] 
[Reis and Kallen, 2008] None of these findings 
were specific to an individual drug. A further sys-
tematic review of antipsychotic therapy during 
early and late pregnancy concluded that, at pre-
sent, we are unable to advise adequately regarding 
malformation risk secondary to in utero exposure 
to SGAs [Gentile, 2010].
Risk of adverse obstetric outcome
There is some evidence to suggest that the overall 
risk for obstetric complications is increased in 
women with severe mental illness independent of 
any associated antipsychotic exposure. A Danish 
study reported an adjusted excess risk of 1.57 
(95% CI 1.36–1.82) for low birth weight and 
1.34 (95% CI 1.17–1.53) for small-for-gesta-
tional-age [Bennedsen et  al. 1999], and an 
Australian study of women with schizophrenia or 
major affective disorder showed a raised risk of 
placental abnormalities and antepartum hemor-
rhage [Jablensky et al. 2005].
The potential risks associated specifically with 
antipsychotic use in pregnancy have included 
gestational diabetes, particularly with the SGAs, 
some of which are known to increase the risk of 
diabetes in general adult patients. They have 
also been associated with prematurity, low and 
high birth weight; the latter may be associated 
with gestational diabetes and caesarian 
delivery.
A large Swedish Medical Birth Register study 
which examined risks associated with maternal 
use of antipsychotic medication (grouping both 
FGAs and SGAs) found these agents were associ-
ated with increased risks for gestational diabetes 
OR 1.78 (1.04–3.01), premature delivery OR 1.73 
(1.31–2.29), low birth weight OR 1.67 (1.21–
2.29) and caesarian delivery OR 1.43 (1.17–1.74) 
[Reis et al. 2008]. An elevated risk for prematurity 
OR 2.46 (1.50–4.11), in those receiving FGAs, 
was also found in a Taiwanese study [Lin et  al. 
2010]. Further studies have found antipsychotic 
medications to be associated with both low birth 
weight and large-for-dates babies; the latter mainly 
associated with exposure to SGAs [McKenna 
et al. 2005; Newham et al. 2008].
Unfortunately, to date none of the study designs 
have been able to adequately control for medica-
tion adherence, psychiatric or physical comorbid-
ity, substance and alcohol abuse, smoking and the 
underlying risks associated with the illness being 
treated.
Risk to the neonate
It remains unclear to what extent antipsychotics 
may complicate the neonatal period due to the 
absence of systematic studies. However, it is rea-
sonable to suspect that there may be an increased 
risk of neonatal withdrawal, extra-pyramidal symp-
toms (EPS) and sedation [Gentile, 2010; Galbally 
et al. 2011]. Exposure to antipsychotics is inevita-
bly coupled with exposure to maternal mental ill-
ness and associated comorbidity such as physical 
illnesses, poor nutrition, smoking, substance and 
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alcohol abuse, and trauma, and it is extremely dif-
ficult to separate the specific influence of antipsy-
chotic medication on fetal outcome.
In 2011, the US Food and Drug Administration 
(FDA) issued a drug safety communication 
regarding concerns about fetal exposure to any 
antipsychotic and the association with abnormal 
muscle movements (EPS) and withdrawal symp-
toms. This warning was prompted by the FDA’s 
database where 69 cases of neonatal EPS or with-
drawal had been identified across both classes of 
antipsychotics. Symptoms of EPS in neonates 
have included motor restlessness, tremor, hyper-
tonicity, dystonia and parkinsonism. A study spe-
cifically of FGAs found hypertonicity, 
tremulousness and poor motor maturity in neo-
nates [Auerbach et al. 1992]. Duration of symp-
toms tended to be transient and brief, although 
one infant exposed to phenothiazines experienced 
hypertonicity for 10 months that was followed by 
subsequent normal motor development.
There is an extreme paucity of data relating to neo-
natal toxicity in newborns exposed to SGAs. It is 
reasonable to suspect that the potential for a medi-
cation to compromise neonatal adaption may 
relate to its level of placental passage. In an impor-
tant prospective observational study of 54 preg-
nant women, Newport and colleagues found the 
placental passage ratio was highest for olanzapine 
[mean = 72.1%, standard deviation (SD) = 
42.0%], followed by haloperidol (mean = 65.5%, 
SD = 40.3%), risperidone (mean = 49.2%, SD = 
33.9%) and quetiapine (mean = 23.8%, SD = 
11.0%) [Newport et al. 2007]. There were higher 
rates of low birth weight (30.8%) and neonatal 
intensive care unit admission (30.8%) among neo-
nates exposed to olanzapine, though these did not 
reach statistical significance [Newport et al. 2007].
Given the paucity of literature and recommenda-
tions for neonatal adaptation or withdrawal fol-
lowing antipsychotic exposure, a literature search 
was performed to identify all papers reporting on 
poor neonatal adaptation associated with antipsy-
chotic use in pregnancy. The PUBMED, 
MEDLINE, EMBASE and PsychINFO data-
bases were searched for papers published in 
English from 1966 to 2013 using the MeSH/free-
text search terms ‘poor neonatal adaptation’, 
‘neonatal abstinence’, ‘neonatal withdrawal’, 
‘neonatal toxicity’, ‘antipsychotic’ and ‘psycho-
tropic’. The results are summarised in Table 1.
Longer term risk of adverse 
neurodevelopmental outcome
A number of published reports have identified 
the offspring of mothers with psychotic illnesses 
as being at greater risk of delays in neurological 
and motor development, generalized cognitive 
deficits and learning difficulties as well as poorer 
performance than controls on specific neurocog-
nitive tasks [Abel and Howard, 2014]. However, 
the potential effects of fetal antipsychotic expo-
sure were not taken into consideration. 
Schizophrenia has also been associated with 
poorer maternal sensitivity towards infants with 
potential to impact on later socioemotional 
development [Snellen et  al. 1999; Wan et  al. 
2007; Wan and Green, 2009]. These studies sug-
gest that the mothers with symptomatic illness, 
potentially from being untreated or under-
treated, is associated with poorer mother–child 
outcomes.
There is an extreme paucity of studies that 
investigate the neurodevelopmental effects of 
prenatal exposure to both FGAs and SGAs. 
There are three studies which have examined 
FGAs. The first is a case controlled study of 
long-term behavioral outcomes following expo-
sure to phenothiazine agents (n = 63) [Stika 
et al. 1990] and the second a retrospective study 
of promethazine exposure (n = 127) [Czeizel 
et al. 1999]. Neither revealed adverse neurocog-
nitive outcomes, although significant methodo-
logical and design issues limit our ability to draw 
conclusions. The third, a larger study described 
the effects of first trimester exposure to FGAs, 
found that the intelligence quotients (IQs) at 4 
years of age for the 1309 exposed children were 
similar to the 48,973 nonexposed children 
[Slone et al. 1977].
The two most recent studies have examined SGAs 
and each followed a prospective case-controlled 
design. Both found an association between in 
utero exposure to SGAs and early delayed neuro-
motor performance [Johnson et  al. 2012; Peng 
et  al. 2013]. The more recent study also found 
delayed cognitive, socioemotional and adaptive 
behavior scores on the Bayley Scales of Infant 
Development at 2 months of age, although reas-
suringly these differences were no longer signifi-
cant by 12 months [Peng et al. 2013]. This finding 
is encouraging, suggesting that, while there may 
be a risk of delay, there is not permanent impair-
ment; further studies with longer follow-up peri-
ods and more comprehensive assessment of child 
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development are required. Given the higher rate 
of exposure to other variables that may impact on 
child development such as smoking, alcohol, illicit 
drugs, as well as maternal mental illness there 
needs to be studies which adequately control for 
this as well. In addition, studies need to follow up 
children long enough so that rigorous measures 
with good predictive validity can be undertaken.
Summary
In a literature review published in 2009, 
Einarson and Boskovic summarised the data 
available from 1996 to 2008 [Einarson and 
Boskovic, 2009]. A general paucity of studies 
examining the safety of antipsychotic medica-
tion during pregnancy was found, so while over-
all no clear evidence of increased risk of birth 
defects or other adverse outcomes was identi-
fied, the authors cautioned any conclusions. A 
2004 Cochrane review of antipsychotic medica-
tion in pregnancy found no studies met the 
inclusion criteria and this resulted in ‘serious 
clinical and ethical problems’ [Webb et al. 2004]. 
For this current review, the 2009 Einarson and 
Boskovic review has been augmented by an 
additional search for all original data assessing 
the safety of antipsychotic drugs during preg-
nancy published in English from 2008 to 
October 2013. The MEDLINE, PUBMED, 
EMBASE and PsychINFO databases were 
searched and the results are summarised in 
Table 2.
Other psychopharmacological treatments 
for bipolar disorder
While this review is limited to antipsychotic treat-
ments in pregnancy, particularly for bipolar disor-
der, there are other psychopharmacological 
treatments that are prescribed either alone or in 
combination with antipsychotic medications. 
These include antiepileptic drugs such as sodium 
valproate, carbamazepine and lamotrigine, and 
also the mood stabilizer lithium carbonate. A sys-
tematic review was published in 2010 outlining 
the risks from pregnancy exposure [Galbally et al. 
2010]. The literature on antiepileptic drugs 
(AEDs) is now substantial with comprehensive 
follow up of children. There is clear evidence of 
an association between certain AEDs, such as 
sodium valproate, and malformation risk. There is 
also an association with sodium valproate, partic-
ularly at doses above 1000 g, with lower cognitive 
outcomes in children exposed [Galbally et  al. 
2010]. The literature on lithium carbonate is far 
more limited, but there is evidence of an increased 
risk of Ebstein’s anomaly, a cardiac malformation 
[Galbally et al. 2010].
Table 1. Neonatal adaptation and exposure to antipsychotic medication in pregnancy.
Study Study type Number of 
subjects
Medication Outcome









Motor and behavioral 
symptoms potentially 
associated with withdrawal 
in neonatal period







(68 with known 
outcome), 197 
retrospective
Risperidone 37 retrospective reports 
of perinatal syndrome, 21 
with behavior or motor 
disorders





















Antipsychotics Neonates exposed to 
antipsychotics in utero 
showed poor neonatal 
motor functioning 
compared with controls, 
speculated to reflect 
withdrawal syndrome
M Galbally, M Snellen et al.
http://taw.sagepub.com 105
Non-pharmacological management
While pharmacological treatment is often impor-
tant in both the treatment and prevention of 
relapse for schizophrenia and bipolar disorder 
(particularly in pregnancy and the postpartum), 
ensuring there is adequate support for women 
and their families cannot be underestimated as 
part of management. There are no specific psy-
chological interventions for women with 
schizophrenia and bipolar disorder in pregnancy 
and in a review of mother–infant interventions for 
women with schizophrenia none were identified 
[Wan et  al. 2008]. Yet limited research suggests 
that women with schizophrenia do have signifi-
cant challenges in early mother–infant interac-
tions and the developing relationship [Snellen 
et al. 1999]. Therefore, it is important as part of 
managing a woman across pregnancy and into the 
Table 2. Antipsychotic medications and pregnancy outcomes from 2008 to October 2013.
Study Study design Number of 
subjects
Medication Findings
Brunner et al. [2013] Prospective 
observational 
study
610 Olanzapine No difference in pregnancy and 
neonatal outcome compared with 
general population data.




(n = 284), atypical 
antipsychotics  
(n = 561), controls 
(n = 1122)
Higher rate of major 
malformations in neonates 
exposed to atypical antipsychotics. 
Higher rates of postnatal 
disorders in neonates observed 
in groups exposed to typical and 
atypical antipsychotics. Preterm 
birth and low birth weight more 
common with exposure to typical 
antipsychotics.





More exposed infants had lower 
birth weight. Lower scores 
on Bayley Scales of Infant 
Development for exposed infants 
at 2 months, but no significant 
difference at 12 months.






(338) or none 
(357,696)
Exposure to antipsychotics 
increased the risk of gestational 
diabetes. No increased risk of SGA. 
Olanzapine/clozapine associated 
with macrocephaly
Johnson et al. [2012] Prospective case 
control
309 Exposed to 
antipsychotics (22), 
antidepressants 
(202) or no 
psychotropics (85)
A history of in utero antipsychotic 
exposure was associated with 
lower scores on a standardized 
test of neuromotor performance 
in 6 month olds compared with 
antidepressant or no psychotropic 
exposure.
Babu et al. [2010] Prospective cohort 
study
70 Olanzapine Olanzapine may be associated with 
higher birth weight.
Lin et al. [2010] Birth data 4176 Typical and 
atypical 
antipsychotics
Higher risk of preterm birth 
for mothers prescribed typical 
antipsychotics. No significant 
difference in rates of low birth 
weight, LGA or SGA.
Wichman [2009] Retrospective case 
file review




One major malformation 
with ventriculomegaly and 
hydrocephalus in an infant 
exposed to aripiprazole. Shortened 
gestational age.
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postpartum to ensure that there is adequate sup-
port for her and her infant and, where possible, 
her partner and family.
Management recommendations for 
antipsychotics use in pregnancy
The recommendations in Box 1 are intended as 
suggestions only, given that many women with 
schizophrenia and bipolar disorder and women 
with other severe mental illnesses that require 
antipsychotic medications will need to continue 
their medication well in the perinatal period. Each 
woman requires an individual management plan 
derived for her circumstances for pregnancy man-
agement. These recommendations were derived as 
part of a specific antenatal clinic for women with 
schizophrenia and bipolar disorder at Mercy 
Hospital for Women (Australia) and were devel-
oped as a collaboration with obstetrics, maternal-
fetal medicine and psychiatry [Galbally et al. 2010].
Postpartum
A clear plan for a woman and her supports (part-
ner and family as appropriate) for postpartum 
care is important for ongoing monitoring and 
care. This should include monitoring of maternal 
Box 1. Management recommendations for antipsychotics use in pregnancy.
 1. Wherever possible, taking into account the potential for pregnancy, preconception consideration should 
be given to the most appropriate form of pharmacological treatment.
 2. Strive for the minimal effective dose of antipsychotic medication. However, the emphasis needs to be on 
effective rather than minimal, and partial treatment should be avoided as this exposes the fetus to 
both the risks of treatment and nontreatment.
 3. Optimize the therapeutic alliance and nonpharmacological treatments.
 4. Establish a close liaison relationship between all disciplines involved in perinatal care: psychiatry, psy-
chology, obstetrics, pediatrics, midwifery, social work, and maternal and child health nursing.
 5. Obtain baseline measures of biological parameters that could be compromised by illness and its 
treatment.
 6. Ensure that a process of obtaining informed consent is followed in which all available information 
regarding the risks and benefits of treatment and nontreatment in the perinatal setting is detailed.
 7. Prescribe 5 mg of folate daily from three months preconception and throughout pregnancy, as there is 
some evidence to suggest that this may be neuroprotective, as well as multivitamins.
 8. Aim for monotherapy wherever possible.
 9. Ideally, a treatment team that specializes in high-risk scenarios should undertake obstetric care.
10. Ensure that adequate monitoring throughout pregnancy occurs of fetal development, obstetric physiol-
ogy and maternal mental state.
11. Ultrasound assessment that focuses on nuchal translucency should be performed at 12 weeks, followed 
by a high-resolution morphology scan performed at 20 weeks’ gestation.
12. Given the potential for increased risk of metabolic syndrome and gestational diabetes with SGAs, glu-
cose tolerance testing rather than glucose challenge testing should be performed early in the second 
trimester (14–16 weeks) and again at 28 weeks’ gestation.
13. Similarly, adequate review of fetal growth (preferably through growth scanning at 28 and 34 weeks and 
further as indicated) is essential given the increased risk of impaired growth, including low and large 
birth weight.
14. At delivery, commence observation for evidence of neonatal withdrawal, toxicity, extrapyramidal symp-
toms, sedation or other adverse effect, and ensure that a careful morphological examination is 
undertaken.
15. Create and implement a Mental Health Care Plan for the postdelivery maternity setting that encourages 
a low stimulus environment, sleep preservation, close liaison between all healthcare providers, and allow 
an extended maternity stay in which observations can be made for any neonatal compromise secondary 
to exposure to psychotropic medications in utero.
16. Establish early warning signs for relapse and pathways to care should this occur.
17. Give clear recommendations and preferences for breastfeeding (either for breastfeeding or not) with 
ideally, a discussion of risks and benefits for particular medications, prior to delivery. Avoid pharmaco-
logical suppression of lactation.
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mental health, infant health and wellbeing, and 
the developing relationship between mother and 
baby. The crucial role of a woman’s supports, 
whether they be a partner or wider family, cannot 
be underestimated and, where possible, commu-
nication and support of her family is important in 
ensuring both maternal and infant wellbeing. 
Clear recommendations about breastfeeding and 
sleep are also helpful for women and their fami-
lies. These recommendations will depend on a 
discussion of the risk and benefits of breastfeed-
ing according to the profile of the specific medica-
tion prescribed and the role of sleep in increasing 
vulnerability to relapse for an individual woman. 
Given the lack of data regarding longer term out-
comes for children exposed to antipsychotic med-
ication in pregnancy, ensuring there is appropriate 
ongoing monitoring of infant and child develop-
ment is optimal.
Conclusion
While there is only limited knowledge about the 
safety of antipsychotic medications in pregnancy, 
this must be balanced with their important role in 
keeping women with schizophrenia and bipolar 
disorder well across this crucial life stage. There is 
evidence to suggest that maternal mental illness is 
associated with not only increased morbidity for 
mother and baby but also maternal mortality 
[Austin et al. 2007]. In addition, mothers who are 
unwell with these illnesses are less sensitive in 
their parenting [Snellen et al. 1999] and this may 
increase the risk of abuse and neglect [Niemi et al. 
2004]. However, this current review has also 
raised the issue of wider use of antipsychotic 
medications for indications beyond schizophrenia 
and bipolar, and given the paucity of data regard-
ing safety of these medications in pregnancy, this 
is an area of use where a careful risk benefit analy-
sis needs to be made.
Future studies are needed which are well 
designed, prospective and follow children up for 
a long enough period to be able to accurately 
assess development. These studies also need to 
account adequately for key confounding varia-
bles such as maternal illness, illicit drugs, smok-
ing and alcohol, as well as accurate measures of 
exposure. This has been achieved to a large extent 
with epilepsy and the anti-epileptic medications 
[Meador et  al. 2008; Galbally et  al. 2010] and 
is now urgently required for antipsychotic 
medications.
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